Share
25 Posts.
lightbulb Created with Sketch. 1
clock Created with Sketch. 06/10/20
22:16
Share
Originally posted by Rich&Poor:
↑
Kazia Therapeutics investor briefing.he will strive to have quarterly paxalisib trial data read outs for the next 2 years . IMO that could have something to do with Kazia's paxalisib being granted Fast Track Designation by FDA, and their registration requirement to submit progressive GBM AGILE data efficacy results and consultations before the final FDA approval. potential of a paxalisib marketing partner any time between 2 to 24 months. At present there are no competitors to paxalisib in the Global pipeline. PI3K is switched on in 90% of Glioblastoma patients, and paxalisib crosses the blood brain barrier.
Expand
Regarding Cantrixil and the need to partner, what about the data that KAZIA was due to report on Cantrixil at the ESMO conference Sep 19 -21? Was data reported on, or referenced, or a release date announced?
